Drug
amivantamab and hyaluronidase-lpuj (human recombinant)
Marketed as RYBREVANT FASPRO.
Generic name
amivantamab and hyaluronidase-lpuj (human recombinant)
Brand names
RYBREVANT FASPRO
First FDA approval
2026-02-13
FDA approval history
| FDA ID | Brand | Approval date | Manufacturer |
|---|---|---|---|
| BLA761484 | RYBREVANT FASPRO | 2026-02-13 | JANSSEN BIOTECH |
Manufacturers
JANSSEN BIOTECH
Frequently asked questions
When was amivantamab and hyaluronidase-lpuj (human recombinant) FDA approved?
Earliest FDA approval on record: 2026-02-13.
What brand names are sold as amivantamab and hyaluronidase-lpuj (human recombinant)?
RYBREVANT FASPRO.
Sources
Appeal a amivantamab and hyaluronidase-lpuj (human recombinant) denial
Upload your denial — DenialHelp drafts a physician-ready appeal letter in five minutes with the right clinical guideline and federal regulation cited. $39 first-level, money back if we can't draft a strong appeal.
Get started →Contact: hello@denialhelp.com